Departments of Spinal Surgery, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China.
Departments of Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China.
Cancer Biomark. 2018;22(1):127-133. doi: 10.3233/CBM-171103.
Blood-circulating microRNAs (miRNAs) have been reported to be used as potential biomarkers in various cancers. MiR-101 has been found to act as a tumor suppressor in many tumor types, but little is known for osteosarcoma. The purpose of this study was to investigate miR-101 expression in osteosarcoma patients and assess its correlation with clinical features and prognosis. Serum samples from 152 osteosarcoma patients and 70 healthy controls were detected using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The data showed that miR-101 expression levels were remarkably underexpressed in serum samples from osteosarcoma patients compared to controls, and the post-treatment serum miR-101 expression was significantly higher than that in the pre-treatment expression. Low serum miR-101 expression was positively associated with advanced clinical stage and distant metastasis. Receiver operating characteristic (ROC) curve analysis showed that serum miR-101 could serve as a useful marker for osteosarcoma diagnosis, with a high sensitivity and specificity. Moreover, patients with high miR-101 expression had longer overall survival and recurrence free survival than those with low miR-101 expression. In addition, both univariate and multivariate analyses showed that serum miR-101 downregulation was associated with shorter overall survival and recurrence free survival. Our present results implicated serum miR-101 might be a useful biomarker for the clinical diagnosis and prognosis of osteosarcoma.
循环血液中的 microRNAs（miRNAs）已被报道可作为多种癌症的潜在生物标志物。miR-101 在许多肿瘤类型中被发现作为肿瘤抑制因子发挥作用，但在骨肉瘤中知之甚少。本研究旨在探讨 miR-101 在骨肉瘤患者中的表达情况，并评估其与临床特征和预后的相关性。使用定量逆转录聚合酶链反应（qRT-PCR）检测了 152 例骨肉瘤患者和 70 例健康对照者的血清样本。数据显示，与对照组相比，骨肉瘤患者血清样本中 miR-101 的表达水平显著下调，且治疗后血清 miR-101 的表达显著高于治疗前。低血清 miR-101 表达与晚期临床分期和远处转移呈正相关。受试者工作特征（ROC）曲线分析表明，血清 miR-101 可作为骨肉瘤诊断的有用标志物，具有较高的敏感性和特异性。此外，高 miR-101 表达的患者总生存时间和无复发生存时间均长于低 miR-101 表达的患者。此外，单因素和多因素分析均表明，血清 miR-101 下调与总生存时间和无复发生存时间较短相关。我们的研究结果表明，血清 miR-101 可能是骨肉瘤临床诊断和预后的有用生物标志物。
